| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Bisantrene HCl (CL216942 and NSC337766), the hydrochloride salt of Bisantrene, is potent inhibitor of topoisomerase II and DNA intercalators with anticancer activity. P-glycoprotein-mediated multiple drug resistance (MDR1) may be studied using it as a model compound. One potential Rac1 inhibitor is bisantrene. DNA-protein crosslinking, DNA single-strand breaks, and inhibition of DNA replication are all caused by bisantrene intercalating with and altering the structure of DNA. While this agent's activity is similar to that of doxorubicin, it does not show cardiotoxicity.
| Targets |
Topoisomerase
|
|---|---|
| ln Vitro |
On oligopurine-oligopyrimidine sequences, bisantrene diHClide enhances DNase I cleavage, whereas on alternating purine-pyrimidine sequences, it somewhat diminishes cleavage activity [1]. The incorporation of [3H]uridine into RNA and [3H]thymidine into DNA is inhibited by bisantrene diHClide [2].
|
| ln Vivo |
A number of experimental cancers, such as P388 leukemia, L1210 leukemia, Liebermann's plasmacytoma, B16 melanoma, colon neoplasia 26, and Ridgway osteosarcoma, respond well to the antineoplastic drug bisantrene diHClide [3]. The effectiveness of bisantrene hydrochloride varies between 1.56 and 150 mg/kg, contingent upon the tumor model employed, treatment frequency, modality, and schedule [3]. Macrophages were pretreated with bisantrene hydrochloride (25, 50, and 100 mg/kg; intraperitoneally; once), and animals injected with P815 tumor cells shown anticancer effects [3]. Neo mice are given dose-dependent doses of bisantrene diHClide (10-150 mg/kg; i.v.; once) to cause leukopenia. Bisantrene hydrochloride toxicity targeting B cells and macrophages [4].
|
| Enzyme Assay |
In ETN buffer (1 mM EDTA, 10 mM Tris, pH 7.0, with NaCl to obtain the desired ionic strength), measurements are performed at 25°C. Spectrophotometric or fluorometric methods are used to observe binding in the ligand absorption or emission region, respectively, following the addition of scalar quantities of DNA to a newly made drug solution. The range of bound drug fractions is 0.15-0.85 in order to prevent significant systematic errors that could arise from experimental errors in extinction coefficients or fluorescence quantum yield. Data are assessed. A Perkin-Elmer Lambda 5 apparatus and an MPF66 fluorometer, both of which have a Haake F3-C thermostat, are used for spectroscopic measurements[1].
|
| References |
[1]. Sissi C, et al. DNA-binding preferences of Bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning. Mol Pharmacol. 1998 Dec;54(6):1036-45.
[2]. Yap HY, et al. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar;43(3):1402-4. [3]. Wang BS, et al. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene). Cancer Res. 1984 Jun;44(6):2363-7. [4]. Aksentijevich I, et al. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity. Clin Cancer Res. 1996 Jun;2(6):973-80. |
| Molecular Formula |
C22H24CL2N8
|
|---|---|
| Molecular Weight |
471.38556
|
| Exact Mass |
470.1500982
|
| Elemental Analysis |
C, 56.06; H, 5.13; Cl, 15.04; N, 23.77
|
| CAS # |
71439-68-4
|
| Related CAS # |
Bisantrene;78186-34-2
|
| Appearance |
Solid powder
|
| SMILES |
C1NC(=NC1)N/N=C/C2=C3C(=C(C4=CC=CC=C24)/C=N/NC5=NCCN5)C=CC=C3.Cl.Cl
|
| InChi Key |
KINULKKPVJYRON-PVNXHVEDSA-N
|
| InChi Code |
InChI=1S/C22H22N8.2ClH/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22;;/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30);2*1H/b27-13+,28-14+;;
|
| Chemical Name |
N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine;dihydrochloride
|
| Synonyms |
NSC337766; CL-216942; NSC 337766; CL216942; CL 216942; NSC-337766
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~5 mg/mL (~10.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1214 mL | 10.6069 mL | 21.2139 mL | |
| 5 mM | 0.4243 mL | 2.1214 mL | 4.2428 mL | |
| 10 mM | 0.2121 mL | 1.0607 mL | 2.1214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04989335 | Recruiting | Drug: Bisantrene Drug: Fludarabine |
Myelogenous Leukemia, Acute | Sheba Medical Center | August 2, 2021 | Phase 2 |
| NCT03820908 | Completed | Drug: Bisantrene | Allogeneic Stem Cell Transplantation Acute Myelogenous Leukemia |
Sheba Medical Center | July 18, 2019 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA